Related Experiment Video
Updated: May 30, 2025
Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
Published on: September 15, 2023
Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments
Edgar Yebran Villegas-Vazquez1, Francisco Pável Marín-Carrasco1, Octavio Daniel Reyes-Hernández1
1Laboratorio de Farmacogenética, UMIEZ, Facultad de Estudios Superiores Zaragoza, Universidad Nacional Autónoma de México, Ciudad de México, Mexico.
Abstract:
Drug repositioning, the practice of identifying novel applications for existing drugs beyond their originally intended medical indications, stands as a transformative strategy revolutionizing pharmaceutical productivity. In contrast to conventional drug development approaches, this innovative method has proven to be exceptionally effective. This is particularly relevant for cancer therapy, where the demand for groundbreaking treatments continues to grow. This review focuses on drug repositioning for ovarian cancer treatment, showcasing a comprehensive exploration grounded in thorough in vitro experiments across diverse cancer cell lines, which are validated through preclinical in vivo models. These insights not only shed light on the efficacy of these drugs but also expand in potential synergies with other pharmaceutical agents, favoring the development of cost-effective treatments for cancer patients.
Insights
Drug repositioning offers a cost-effective strategy for developing novel ovarian cancer treatments. This review explores existing drugs repurposed for ovarian cancer, validated through in vitro and in vivo studies.
Area of Science:
- Oncology
- Pharmacology
- Drug Discovery
Background:
- Drug repositioning identifies new uses for existing drugs, accelerating pharmaceutical development.
- Conventional drug development is lengthy and expensive, highlighting the need for innovative approaches.
- Ovarian cancer requires novel therapeutic strategies due to increasing treatment demands.
Purpose of the Study:
- To review drug repositioning strategies specifically for ovarian cancer treatment.
- To explore the efficacy of repurposed drugs in preclinical ovarian cancer models.
- To identify potential synergistic combinations for cost-effective ovarian cancer therapies.
Main Methods:
- Comprehensive review of existing literature on drug repositioning for ovarian cancer.
- Analysis of in vitro experimental data across various ovarian cancer cell lines.
- Validation of drug efficacy through preclinical in vivo models.
Main Results:
- Demonstrated efficacy of several repositioned drugs against ovarian cancer cell lines.
- Preclinical in vivo studies confirmed the therapeutic potential of identified drugs.
- Identified potential synergistic effects when combining repositioned drugs with other agents.
Conclusions:
- Drug repositioning is a viable and effective strategy for ovarian cancer therapy development.
- Repurposed drugs show promise as cost-effective treatment options for ovarian cancer patients.
- Further investigation into drug synergies could lead to enhanced ovarian cancer treatment regimens.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers
01:26Drug Discovery: Overview